- Antibodies
- New
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Tag
- Peptides
- Biological Process >
- Cellular Compartment >
- Disease >
- Molecular Function >
- Pathway Biocarta >
- Pathway KEGG >
- Pathway Panther >
- Tissue >
- Amino Acids
- Tag
- Biological Process >
- Proteins
- RNAi
- FL cDNA Clones
- Cell/Tissues/Lysates
INHA Antibody (N-term)Purified Rabbit Polyclonal Antibody (Pab)
| Country | United States
Ordering Information
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others 
|
|||
|---|---|---|---|---|
| Catalog # | Size | Availability | Price | |
| AP6722a | 0.1 mg 400 ul | In Stock | $ 255.00 | DISCONTINED INQUIRE CLICK INQUIRE Add to cart |
- Specification
- Citiations : 0
- Reviews
- Protocols
- Backgrounds
INHA Antibody (N-term) - Product info | |
| Application | WB, IHC, IF, FC
|
| Primary Accession | P05111 |
| Reactivity | Human |
| Concentration | 0.25 mg/ml |
| Isotype | Rabbit Ig |
| Calculated MW | 39670 Da |
INHA Antibody (N-term) - Additional info | |
| Gene ID 3623 | |
| Other Names INHA; Inhibin alpha chain | |
| Target/Specificity This INHA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 86~116 amino acids from the N-terminal region of human INHA. | |
| Dilution WB~~1:100~500WB~~1:1000 IHC~~1:10~50 IF~~1:10~50 FC~~1:10~50 | |
| Format Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is prepared by Saturated Ammonium Sulfate (SAS) precipitation followed by dialysis against PBS. | |
| Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. | |
| Precautions INHA Antibody (N-term) is for research use only and not for use in diagnostic or therapeutic procedures. | |
INHA Antibody (N-term) - Protein Information | |
| Name INHA | |
| Function Inhibins and activins inhibit and activate, respectively, the secretion of follitropin by the pituitary gland Inhibins/activins are involved in regulating a number of diverse functions such as hypothalamic and pituitary hormone secretion, gonadal hormone secretion, germ cell development and maturation, erythroid differentiation, insulin secretion, nerve cell survival, embryonic axial development or bone growth, depending on their subunit composition. Inhibins appear to oppose the functions of activins | |
| Cellular Location Secreted. | |
| Tissue Location Originally found in ovary (granulosa cells) and testis (Sertoli cells), but widely distributed in many tissues including brain and placenta. In adrenal cortex expression is limited to the zona reticularis and the innermost zona fasciculata in the normal gland, extending centripetally into the zona fasciculata in hyperplasia. Also found in adrenocortical tumors Also expressed in prostate epithelium of benign prostatic hyperplasia, in regions of basal cell hyperplasia and in nonmalignant regions of high grade prostate cancer. Only circulating inhibin B is found in male, whereas circulating inhibins A and B are found in female | |
INHA Antibody (N-term) - Related products
AP6722a: INHA Antibody (N-term)
AP6722c: INHA Antibody (Center)
DC01965: Human INHA cDNA Clone
LY10039a: INHA Over-expression Lysate
BP6722a: INHA Antibody (N-term) Blocking Peptide
BP6722c: INHA Antibody (Center) Blocking Peptide
INHA Antibody (N-term) - Application data
-
Western blot analysis of INHA (arrow) using rabbit polyclonal INHA Antibody (N-term) (Cat. #AP6722a). 293 cell lysates (2 ug/lane) either nontransfected (Lane 1) or transiently transfected with the INHA gene (Lane 2) (Origene Technologies).
-
INHA Antibody (N-term) (RB18802) IHC analysis in formalin fixed and paraffin embedded human testis tissue followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the INHA Antibody (N-term) for immunohistochemistry. Clinical relevance has not been evaluated.
-
Confocal immunofluorescent analysis of INHA Antibody (N-term)(Cat#AP6722a) with Hela cell followed by Alexa Fluor 488-conjugated goat anti-rabbit lgG (green). DAPI was used to stain the cell nuclear (blue).
-
INHA Antibody (N-term) (Cat. #AP6722a) flow cytometric analysis of 293 cells (right histogram) compared to a negative control cell (left histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.
INHA Antibody (N-term) - Research Areas
Abgent welcomes feedback from its customers.
If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abgent.com.
Thank you for your support.
Provided below are standard protocols that you may find useful for product applications.
BACKGROUND
The inhibin alpha subunit joins either the beta A or beta B subunit to form a pituitary FSH secretion inhibitor. Inhibin has been shown to regulate gonadal stromal cell proliferation negatively and to have tumour-suppressor activity. In addition, serum levels of inhibin have been shown to reflect the size of granulosa-cell tumors and can therefore be used as a marker for primary as well as recurrent disease. However, in prostate cancer, expression of the inhibin alpha-subunit gene was suppressed and was not detectable in poorly differentiated tumor cells. Furthermore, because expression in gonadal and various extragonadal tissues may vary severalfold in a tissue-specific fashion, it is proposed that inhibin may be both a growth/differentiation factor and a hormone.
REFERENCES
Balanathan,P., Br. J. Cancer 100 (11), 1784-1793 (2009) Mason,A.J., Mol. Endocrinol. 10 (9), 1055-1065 (1996)
